Solvent detergent treated pooled plasma and reduction of allergic transfusion reactions.
Andrea M McGonigleEshan U PatelKevin M WatersAlison R MoliternoSandra K ThomanSonja O VozniakPaul M NessKaren E KingAaron A R TobianParvez M LokhandwalaPublished in: Transfusion (2019)
S/D plasma has promise as an effective product to reduce the risk of ATRs in TTP patients. Given the high risk of ATR in TTP patients, consideration of S/D plasma instead of untreated plasma for TPE in these patients may be warranted, especially for patients with a history of moderate to severe ATR. More extensive studies are needed to confirm these findings.
Keyphrases
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- randomized controlled trial
- cardiac surgery
- clinical trial
- machine learning
- acute kidney injury
- high intensity
- early onset
- study protocol
- artificial intelligence
- sickle cell disease
- dna repair
- allergic rhinitis
- solar cells